Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.42 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318315 | 1.00 | FPR2 (0.48) | FPR2HPGDPIK3CDPIK3R2PIK3CA | |
| SCHEMBL29115051 | 0.93 | FPR2 (0.46) | FPR2HPGDPIK3CDPIK3R2PIK3CA | |
| SCHEMBL26981244 | 0.93 | FPR2 (0.46) | FPR2HPGDPIK3CDPIK3R2PIK3CA | |
| SCHEMBL29115029 | 0.93 | FPR2 (0.46) | FPR2HPGDPIK3CDPIK3R2PIK3CA | |
| SCHEMBL30318136 | 0.93 | GPR119 (0.45) | FPR2KMT2AUSP30 | |
| SCHEMBL30318460 | 0.93 | GPR119 (0.45) | FPR2KMT2AUSP30 | |
| SCHEMBL31675895 | 0.91 | HPGD (0.48) | FPR2HPGDPIK3CAPIK3CGKMT2A | |
| SCHEMBL30318195 | 0.91 | HPGD (0.48) | FPR2HPGDPIK3CAPIK3CGKMT2A | |
| SCHEMBL30318354 | 0.91 | HPGD (0.48) | FPR2HPGDPIK3CAPIK3CGKMT2A | |
| SCHEMBL22118568 | 0.88 | FPR2 (0.42) | FPR2PIK3CDPIK3CAUSP30SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-B1 | FGFR2 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-08-21 | — | — | US | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | FPR2 4200/4885HPGD 2512/4885PIK3CD 2062/4885 |
| US-20250263409-A1 | FGFR2 INHIBITOR COMPOUNDS | FGFR2, FGFR1, FGFR3 | FPR2 1117/4885HPGD 4734/4885PIK3CD 1240/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | FPR2 4200/4885HPGD 2512/4885PIK3CD 2062/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | FPR2 4200/4885HPGD 2512/4885PIK3CD 2062/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | FPR2 4200/4885HPGD 2512/4885PIK3CD 2062/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | FPR2 4200/4885HPGD 2512/4885PIK3CD 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.